<DOC>
	<DOCNO>NCT01042379</DOCNO>
	<brief_summary>The purpose study advance ability practice personalize medicine learn new drug agent effective type breast cancer tumor learn early indicator response ( tumor analysis prior surgery via magnetic resonance imaging ( MRI ) image along tissue blood sample ) predictor treatment success .</brief_summary>
	<brief_title>I-SPY 2 TRIAL : Neoadjuvant Personalized Adaptive Novel Agents Treat Breast Cancer</brief_title>
	<detailed_description>I-SPY 2 compare efficacy novel drug combination standard chemotherapy efficacy standard therapy alone . The goal identify improve treatment regimen subsets basis molecular characteristic ( biomarker signatures ) disease . As described previous adaptive trial , regimens show high Bayesian predictive probability effective standard therapy graduate trial correspond biomarker signature ( ) . Regimens drop show low probability improve efficacy biomarker signature . New drug enter undergone test complete evaluation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm invasive cancer breast Clinically radiologically measureable disease breast diagnostic biopsy , define long diameter great equal 25 mm ( 2.5cm ) No prior cytotoxic regimen allow malignancy . Patients may prior chemotherapy prior radiation therapy ipsilateral breast malignancy . Prior bisphosphonate therapy allow Age ≥18 year ECOG performance status 01 Willing undergo core biopsy primary breast lesion ass baseline biomarkers Nonpregnant nonlactating No ferromagnetic prosthesis . Patients metallic surgical implant compatible MRI machine eligible . Ability understand willingness sign write informed consent ( ISPY TRIAL Screening Consent ) Eligible tumor must meet one follow criterion : Stage II III , T4 , N , M0 , include clinical pathologic inflammatory cancer Regional Stage IV , supraclavicular lymph node site metastasis Any tumor ER/PgR status , HER2/neu status measure local hospital pathology laboratory meet tumor assay profile describe protocol section 4.1.2F Normal organ marrow function : Leukocytes ≥ 3000/μL , Absolute neutrophil count ≥ 1500/μL , Platelets ≥ 100,000/μL , Total bilirubin within normal institutional limit , unless patient Gilbert 's disease , bilirubin must ≤ 2.0 x ULN , AST ( SGOT ) /ALT ( SGPT ) ≤ 1.5 x institutional ULN , creatinine &lt; 1.5 x institutional ULN No uncontrolled severe cardiac disease . Baseline ejection fraction ( nuclear image echocardiography ) must ≥ 50 % No clinical image evidence distant metastasis PA Lateral CXR , Radionuclide Bone scan , LFTs include total bilirubin , ALT , AST , alkaline phosphatase Tumor assay profile must include follow : MammaPrint High , ER status , HER2 status , MammaPrint Low , ER negative ( &lt; 5 % ) , HER2 status , MammaPrint Low , ER positive , HER2/neu positive one three method use ( IHC , FISH , TargetPrint™ ) Ability understand willingness sign write informed consent document ( ISPY 2 TRIAL Consent # 2 ) Use investigational agent within 30 day start study treatment History allergic reaction attribute compound similar chemical biologic composition study agent accompany supportive medication . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>I-SPY 2</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>Adaptive</keyword>
	<keyword>pCR</keyword>
	<keyword>Pathologic Complete Response</keyword>
	<keyword>Biomarkers signature</keyword>
	<keyword>MRI Volume</keyword>
</DOC>